Lunit (CEO Seo Beom-seok) , a medical artificial intelligence (AI) company, announced on the 19th that it has signed a supply contract with Akumin, a US imaging diagnostic service provider, for its 3D-based AI breast cancer diagnosis solution, 'Lunit Insight DBT.'
Headquartered in Plantation, Florida, Acumin operates over 150 imaging centers and numerous mobile medical imaging units across 47 states and partners with over 1,000 healthcare institutions and physician groups. When healthcare institutions find it difficult to establish their own imaging and cancer treatment services, Acumin provides them through outsourcing.
Lunit Insight DBT, supplied under this agreement, is an AI solution that analyzes 3D breast computed tomography (DBT) imaging data to support medical professionals' diagnostics. It is gradually gaining market share in the US market, where 3D mammography is well-developed, and Acumin's nationwide network will enable more patients to benefit from AI-based precision cancer diagnosis services.
Acumin is pursuing the introduction of cutting-edge solutions to improve the quality of care and expand patient accessibility, and Lunit also plans to focus on expanding its imaging diagnostic network in the United States through this supply.
“Our partnership with Acumin will enable patients across the United States to access AI-based cancer diagnosis services,” said Seo Beom-seok, CEO of Lunit. “We will continue to focus on developing and disseminating AI solutions that meet the needs of the medical field, leading the shift in the global cancer diagnosis paradigm.”
“The Lunit AI solution will provide real value to patients and medical professionals based on clinical data and field verification,” said Nasir Siddiqi, Chief Medical Officer of Acumin. “This introduction will improve customer satisfaction with Acumin’s imaging diagnostic services.”
- See more related articles
You must be logged in to post a comment.